Mylan Tells Fed. Circ. That Sanofi Insulin Patents Not Special
Mylan Pharmaceuticals told the Federal Circuit on Thursday there's no reason to reinstate a pair of Sanofi-Aventis patents covering a fix for some insulin medications, arguing in a hearing that the...To view the full article, register now.
Already a subscriber? Click here to view full article